在肺腺癌中,DOT1L通过H3K79me2介导的免疫检查点的表观遗传激活来促进免疫逃避
Xiwu Rao1,2, Xiangjun Qi1, Zhiqiang Chen1,3
1Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Frontiers in immunology
|March 16, 2026
概括
DOT1L 免疫检查点的表观遗传激活驱动肺癌免疫逃避. 抑制DOT1L抑制瘤生长并重塑瘤免疫微环境,提供一种潜在的治疗策略.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症免疫学 癌症免疫学
- 分子瘤学分子瘤学
背景情况:
- 组织素甲基转移酶DOT1L对于H3K79甲基化至关重要.
- 在肺腺癌 (LUAD) 的瘤免疫微环境 (TME) 中DOT1L的作用在很大程度上是未知的.
- 免疫逃避是癌症的标志,通常由免疫检查点介导.
研究的目的:
- 为了研究DOT1L在调节LUAD中的免疫逃避中的功能.
- 阐明DOT1L影响TME的机制.
- 评估在LUAD中DOT1L抑制的治疗潜力.
主要方法:
- 对TCGA和单细胞RNA-seq数据的综合分析.
- 染色体免疫沉测序 (ChIP-seq) 用于识别DOT1L目标.
- 在体外和体外模型中使用SGC0946进行DOT1L的药理抑制.
- 临床LUAD样本的分析.
主要成果:
- 在LUAD中,高DOT1L表达与预后不佳,细胞毒性免疫细胞减少和免疫检查点表达增加 (PD-L1,PD-1,LAG3,CD276) 相相关.
- DOT1L在JAK1/STAT3和免疫检查点基因的促进者中丰富H3K79me2.
- DOT1L抑制抑制了JAK1/STAT3/PD-L1轴,减少了PD-1+ T细胞,减轻了肺转移,并改善了生存率.
- DOT1L抑制通过降低关键检查点和增强抗瘤细胞因子 (TNF-α,IFN-γ) 生产来重塑TME.
结论:
- DOT1L是LUAD中免疫抑制的关键表观遗传调节剂.
- DOT1L通过表观遗传激活免疫检查点来协调免疫逃避.
- 针对DOT1L是通过克服免疫逃避来为LUAD提供一个有前途的治疗策略.
相关概念视频
Epigenetic Regulation
4.1K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
4.1K
Epigenetic Regulation
34.2K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
34.2K
